• CENTRE FOR COMMERCIALIZATION OF CANCER IMMUNOTHERAPY C3I

C3i

ACCELERATING MARKET
ACCESS OF BREAKTHROUGH
INNOVATIONS TO FIGHT CANCER

News

Triumvira Immunologics Announces Strategic Relationship for GMP Manufacturing with Centre for Commercialisation of Cancer Immunotherapy

Triumvira Immunologics, a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack multiple cancers, today announced a strategic relationship with the Centre for Commercialisation of Cancer Immunotherapy (C3i), a catalyst for accelerating market access of breakthrough innovations to fight cancer. Under the terms of the agreement, C3i will deliver cell therapy products for Triumvira’s global Phase 1 and 2 clinical trials and has committed to underwrite an investment in the company.
MORE